user_mobilelogo

DONATIONS

You can help to ensure the continuation of this valuable work by making a financial contribution to the Foundation.

Even the smallest donation is welcome.

Patient helped by nurse nurses helping patient.


Please help us by:

CASH — giving a cash payment in a sealed envelope, addressed to your Consultant in charge and marked S.D.N.F.
CHEQUES — cheques made payable to S.D.N.F. and sent to your Consultant in charge, c/o Depatment of Neuroscience, Royal Preston Hospital, Sharoe Green Lane PRESTON PR2 4HT.
GIFT AID — by covenanting a fixed sum annually to the Department of Neuroscience, whereby we will be able to reclaim the income tax and so increase the value of the gift. We will supply a form of covenant on request, or download a form.
FUND-RAISING —  holding a fund raising event which will not only raise money but will also highlight the work of the Foundation.


IF you want to find out more, or need a more direct approach you can contact the secretary by email - This email address is being protected from spambots. You need JavaScript enabled to view it.

Why we need your help

The Foundation is based at the Department of Neuroscience in Preston, which serves a population of approximately 2 million people in the Health Districts of Preston, Chorley, South Ribble, Blackpool, Blackburn, Burnley, Lancaster and South Cumbria. Each year the Department cares for more than 2000 inpatients and more than 5000 outpatients.

T 5 1

We have achieved a great deal in the treatment of; Head injuries, brain and spinal tumours, strokes, cerebral haemorrage, multiple sclerosis, motor neurone disease and Parkinson’s disease.


The cost of providing this excellent service is enormous.

Sadly, there is very little available from Government or State funding to spend on Education and Research.

If the Department is to continue its pioneering work at the frontiers of the Neurosciences, it must maintain and expand its research and training facilities.

 

 To download our donation form for Gift Aid, please click on the button below.

download

The Annual Lecture is held in May every year in the Education Centre at Royal Preston Hospital,  when a prominent Neuroscientist is invited to deliver a lecture to an audience of medical practitioners from the North West. 

The lectures have become a landmark in the scientific programme of the medical community. 

 

PAST LECTURES -

2017 - Professor John Darling - Prof of Neuro-oncology, Wolverhampton

'Brain Cancer - how long until biology provides new therapies?'

2016 - Professor Tim Solomon - Prof of Neurology, University of Liverpool

'Neurological Infections. Locally, Nationally and Internationally'

2015 - Professor Sir Graham Teasdale - Retired Prof of Neurosurgery, Glasgow

'Glasgow Coma Scale - past, present and future'

2014 - Professor Colin Blakemore - Prof of Neuroscience and Philosopjy, London -

'Vision Impossible'

2013 - Professor Laurent Spelle, MD, PhD, Professor of Neuroradiology, Beaujon Hospital Paris

The 'Role of Endovascular Interventions in Vascular Conditions of the Brain'


 

Previous Sponsors

2017 - Severn Health Care, Cryolife

2016 - Biogen, Stryker, Severn Health Care

2015 - BBraun, Codman, Severn Health Care, Cryolife, Brainlab

2014 - Tissuemed, Codman, Stryker

2013 - Microvention UK

2012  UCB Pharma, Microvention

2011 Eli Lilley

2010 Zimmer-Spine

2003 - 2009  Teva Pharmaceuticals (Excluding 2007)

2002 Teva Pharmaceuticals, Britannia Pharmaceuticals, UCB Pharma

2001 Shearing Healthcare, Pharmacia & Upjohn, Novartis, Britannia Pharmaceuticals, Ipsen

2000 Leica Microsystems Ltd

1999 Zeneca Pharmaceuticals Ltd, Glaxo, Britannia Pharmaceuticals Ltd, Smith Kline Beecham,
Leica Microsystems UK L td, Rhone Poulenc Rorer, Elan Pharmaceuticals Ltd


1998 Smith, Kline & Beecham, Pharmacia & Upjohn, Parke Davis


1996 Speywood Pharmaceuticals Ltd

 

 

 

PROTOCOL FOR RESEARCH GRANT APPLICATIONskullaneurysm3

1. Introduction

The Foundation supports research undertaken by staff of all disciplines within Neuroscience at Royal Preston Hospital and the University of Central Lancashire.

The funding for these purposes is of course limited, and the Trustees wish to ensure competing bids are considered in both a timely and consistent manner. This paper sets out the process by which such applications will be handled from 1st April and 1st October each year.

2. Timescales

The Trustees will consider applications twice a year:

At their first meeting following 1st April
And the equivalent meeting following 1st October.
Applications shall be lodged with the Secretary  by 1st March or 1st September.  .
Dates of Trustee meetings can be obtained from Gwen Quayle - Please click here

3. Applications

Applications may be made by either; completion of the pro forma attached below, OR, downloading the PDF file of the form and the letter of consent in Word format, completing and returning both via email to Gwen Quayle. Incomplete applications will not be considered.

4. Foundation Award

This Award will be given to a young Neuroscientist from the Preston Unit (excluding Consultants) or UCLAN for an original paper relating to a Neuroscience topic.

The work should not have been published or presented elsewhere in the same format. The criteria for scoring are originality, methodology, presentation of results, discussion, conclusions and the potential for clinical application. The completed manuscript (including an electronic version) should be submitted to the Foundation Secretary by 1st March  or 1st September.

The Award will consist of financial sponsorship up to £1,500 to visit a Centre of Excellence in the Neuroscience field to be taken within 2 years of accepting the award. Further details from Gwen Quayle, Secretary.

Name *
Position: *
Contact Number: *
Contact Email: *
Description of proposed research: *
Funding sought from the foundation,: *
Sponsor’s supporting statement: *
Directorate Manager’s statement: *
Have you applied to the appropriate ethics board for approval?
Confirm that you have read the Terms and Conditions *

5. Recent Award Winners

2005/06

Dr Rajiv Mohanraj

Pharmacogenomics in Epilepsy: Role of Sodium Channel Gene Polymorphisms in Determining Response to Antiepileptic Drug Treatment.

Mr R V Iyer

A Feasibility Study of Chemosensitivity Testing in Primary Cultures from Malignant Gliomas and Comparison of Colorimetric and Luminescent Cell Proliferation Assays

2008/09

Dr David Paling

Prospective study on the outcome of tilt table testing and carotid sinus massage in 290 consecutive elderly adults with syncope or  unexplained falls, and of treatment of 135 of these patients with proven neurocardiogenic syncope with midodrin

2009/10

Ms Cherith Sutton

P-gP and MRP Immunostaining in Gliomas.

2012/13

Dr Nick Clarleton- Bland

Embedding simulation into training to support curriculum delivery and enhance patient safety:  The EVD Project

2015/16

Dr Mark Maskery

The utility of FDG-PET/CT in clinically suspected paraneoplastic neurological syndrome:  a literature review and retrospective case series

2016/17

Dr Anthony Stead

Assessing Premature Mortality Due to Head Injury in England and Wales over a 10 year period.

1. Brain Tumour North West Tissue Bank

The Brain Tumour North West (BTNW) Tissue Bank

The Brain Tumour North West (BTNW) Tissue Bank plays a major role in NW regional neuro-oncology research collaboration. Providing researchers access to tumour tissue and blood samples is central to advancing the understanding of tumour development and testing potential treatments.

It is testament to the generosity of our patients and their relatives at such a difficult time in their lives, that they overwhelming support the collection of this tissue for research purposes.

The BTNW bank has the approval of the National Research Ethics Service as a Research Tissue Bank and is held under a Human Tissue Authority licence at Lancashire Teaching Hospitals NHS Trust in Preston.

The SDNF generously provide funding for the technical and administrative support to run this project. This priceless resource encourages new researchers into the field, builds upon basic research themes and allows their translation into better diagnostic strategies and treatments. http://www.btnw.org.uk/

2. Brain Cancer - Glioblastoma Multiforme

Sydney Driscoll Abstract - Chris Sherer (June 2012)

Cancer is one of the biggest killers internationally, and brain tumours in particular strike largely independent of age, race, sex or lifestyle. Glioblastoma multiforme is the most aggressive form of brain tumour, and typically carries with it a poor prognosis.

Figure – The structure of indole (left), 223α (centre) and 209 (right)


In attempts to overcome the low quality of life and poor prognosis of glioma patients, we are grateful to the Sydney Driscoll Neuroscience Foundation and Brain Tumour North West for funding to support a PhD project aimed at making new drugs to potentially treat this disease.

The privileged structure of the indole nucleus (Fig 1) has been described as 'one of the most ubiquitous heterocyclic structures found in nature'.[1] Due to its planarity, small size and rigidity, the indole nucleus makes an ideal scaffold on which to attach functionality and thus create highly specialised drugs.

This project continues the development of two compounds that have previously been identified as having anticancer activity against glioblastoma cell lines (Fig. 1). 223α is a derivative of indole-3-carbinol, an indole-containing compound whose anti-cancer activity has been known for over 30 years, yet has only recently been shown to be active against glioblastoma cell lines by the Snape group.[2] Compound 209 is a novel compound found by the Snape group to also be active against glioblastoma cell lines.[2]

The versatile Truce-Smiles rearrangement, which has been developed by the Snape group to access a wide range of indoles, will be one of the many reactions used to synthesise a wide range of 223α and 209 derivatives. These derivatives will then be tested in preclinical studies, using colorimetric cell toxicity assays, to try and discern structure-activity relationships for both classes of compounds against a variety of established glioma cell lines and short term cultures. This will hopefully lead to a small series of highly active and rationally designed compounds that can be put forward as potential drug candidates.

[1] D. A. Horton, G. T. Bourne, M. L. Smythe, Chem. Rev. 2003, 103, 893-930.

[2] S. Prabhu, Z. Akbar, F. Harris, K. Karakoula, R. Lea, F. Rowther, T. Warr, T. Snape, Bioorg. Med. Chem. 2013, 21, 1918-1924.

3. "Arterial Spin Labelling Reveals Prolonged Arterial Arrival Time In Idiopathic Parkinson's Disease"

www.ncbi.nlm.nih.gov/pmc/articles/PMC4215519/pdf/main.pdf

The Library is located on Ward 2A of Royal Preston Hospital and offers a range of library resources such as books and journals (both print and electronic) pertaining to the Neurosciences. We encourage the Neurosciences Medical and Nursing staff to use the Library as much as possible. We are building up our collections of resources so as to meet the increasing needs of our users. All library resources are for reference use only but a photocopying facility is available in the library. A photocopier, computer, and study area are also available for research purposes. Please contact the librarian for further enquiries.

Librarian Contact Details
Address: Ward 2A
Department of Neuroscience
Royal Preston Hospital
Sharoe Green Lane North
Preston PR2 9HT
Part-time Voluntary Librarian:Christine Hughes
Working Hours: Tuesday 9am - 1pm.